Suchen
Merus NV
MRUSZur Watchlist hinzufügen
90.000USD
0.0000.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
6.83BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Merus NV Unternehmen
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Merus NV Informationen
BörsenkürzelMRUS
Name des UnternehmensMerus NV
IPO-datumMay 19, 2016
CEOLundberg (Sven Ante)
Anzahl der mitarbeiter260
WertpapierartOrdinary Share
GeschäftsjahresendeMay 19
AddresseYalelaan 62
StadtUTRECHT
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl3584 CM
Telefon310302538800
Websitehttps://merus.nl/
BörsenkürzelMRUS
IPO-datumMay 19, 2016
CEOLundberg (Sven Ante)
Führungskräfte von Merus NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-17.99%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Paolo Pucci
Mr. Paolo Pucci
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sherri Spear
Ms. Sherri Spear
Investor Relations and Corporate Communications
Investor Relations and Corporate Communications
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
168.44K
-17.99%
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Gregory D. (Greg) Perry
Mr. Gregory D. (Greg) Perry
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Leonard (Len) Kanavy
Mr. Leonard (Len) Kanavy
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Merus NV?
Die fünf größten Anteilseigner von Merus NV sind: Dr. Sven Ante (Bill) Lundberg, M.D.
Wie viele Institutionen halten Anteile an Merus NV (MRUS)?
Mit Stand vom 2025Q4 halten 498 Institutionen Anteile an Merus NV, mit einem Gesamtmarktwert von etwa 69.89M, was 92.15% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -15184959.00 gestiegen.
